eptinezumab Vyepti
Selected indexed studies
- ** (, 2023) [PMID:38498646]
- Eptinezumab: First Approval. (Drugs, 2020) [PMID:32266704]
- ** (, 2023) [PMID:37883615]
_Worker-drafted node — pending editorial review._
Connections
eptinezumab Vyepti is a side effect of
Sources
- Migraine overview and summary of current and emerging treatment options. (2019) pubmed
- Eptinezumab. (2006) pubmed
- Eptinezumab: First Approval. (2020) pubmed
- Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. (2020) pubmed
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). (2020) pubmed
- Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. (2022) pubmed
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. (2021) pubmed
- PMID:38498646 (2023) pubmed
- PMID:37883615 (2023) pubmed
- Eptinezumab (Vyepti) for migraine prevention. (2020) pubmed